Table 1 Characteristic of the included trials
First author | Year | Country | Design | Intervention | N | Age | Gender (Male/Female) | PD/PPPD | NOS |
|---|---|---|---|---|---|---|---|---|---|
Aghalarov | 2018 | Germany | Retro | Isolated PJ Conventional PJ | 25 50 | 65 ± 11 64 ± 11 | 10/15 17/33 | 5/20 6/44 | 7 |
Ballas | 2010 | Greece | Retro | Isolated PJ Conventional PJ | 46 42 | 64.4 ± 9.5 60.9 ± 11.5 | 29/17 23/19 | 38/8 25/17 | 7 |
Ben-Ishay | 2019 | Israel | Retro | Isolated GJ Conventional PJ | 52 127 | 68.2 ± 9.6 68 ± 13.7 | 26/26 62/65 | 52/0 127/0 | 8 |
Busquets | 2018 | Spain | RCT | Isolated GJ Conventional PJ | 40 40 | 68.1 ± 11.7) 65.6 ± 10.9) | 24/16 24/16 | 40/0 40/0 | 9 |
Casadei | 2008 | Italy | Pro | Isolated PJ Conventional PJ | 18 20 | 65.7 ± 10.0 56.3 ± 11.0 | 11/7 13/7 | 14/4 11/9 | 8 |
Chhaida | 2018 | Tunisia | Retro | Isolated PJ Conventional PJ | 35 35 | 61 (44–74) 61 (44–74) | 12,23 12,23 | 35/0 35/0 | 7 |
EL-SOROGY | 2016 | Egypt | RCT | Isolated PJ Conventional PJ | 20 20 | 53 (29–66) 56 (34–73) | 10/10 16/4 | 0/20 0/20 | 7 |
Grobmyer | 2008 | USA | Retro | Isolated PJ + GJ Conventional PJ | 112 588 | 68 (36–83) 70 (38–90) | 70/42 288/300 | 112/0 588/0 | 8 |
Kaman | 2008 | India | Retro | Isolated PJ Conventional PJ | 60 51 | 51 ± 13.3 50 ± 13.6 | 39/21 35/16 | 60/0 42/9 | 8 |
Ke | 2013 | China | RCT | Isolated PJ Conventional PJ | 107 109 | 58.3 ± 5.9 59.3 ± 6.6 | 51/56 50/59 | 107/0 109/0 | 8 |
Li | 2015 | China | Retro | Isolated PJ Conventional PJ | 43 43 | 54.2 ± 9.6 53.8 ± 10.2 | 27/16 27/16 | 12/31 10/33 | 7 |
Perwaiz | 2006 | India | Retro | Isolated PJ Conventional PJ | 53 55 | 53.3 ± 12.1 53.5 ± 10.1 | 40/13 41/14 | 53/0 53/0 | 7 |
Shimoda | 2013 | Japan | RCT | Isolated GJ Conventional PJ | 49 52 | 65.7 ± 11.1 66.5 ± 9.8 | 28/21 32/20 | 49/0 52/0 | 8 |
Tani | 2014 | Japan | RCT | Isolated PJ Conventional PJ | 75 76 | 69.6 ± 7.9 68.0 ± 8.9 | 39/36 42/34 | 2/73 7/70 | 8 |